Pharmacology and therapeutic applications of A3 receptor subtype

被引:72
作者
Fishman, P [1 ]
Bar-Yehuda, S
机构
[1] Can Fite BioPharma, IL-49160 Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Rabin Med Ctr, Felsenstein Med Res Ctr,Lab Clin & Tumor Immunol, IL-49100 Petah Tiqwa, Israel
关键词
adenosine; A(3) adenosine receptor; cancer therapy; myeloprotection; cardioprotection; neuroprotection; anti-inflammatory; asthma;
D O I
10.2174/1568026033392147
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The present study summarizes the biological effects elicit upon A(3) adenosine receptor (A(3)AR) activation in normal and tumor cells. Anti-inflamatory response is mediated upon A(3)AR activation in neutrophils, eosinophils and macrophages via direct effect on cell degranulation or the production of anti-inflamatory cytokines. In basophils, which highly express A(3)AR, degranulation and mediator release upon receptor activation lead to pro-inflammatory effects resulting in bronchospasm and asthma. In other normal cells such as cardiomyocytes, neuronal cells and bone marrow cells A(3)AR activation induces cytoprotective effects in vitro. In vivo, A(3)AR agonists act as cardio- and neuroprotective agents and attenuate ischemic damage. Furthermore, agonists to A(3)AR induce granulocyte colony stimulating factor (G-CSF) production and myeloprotective effect in chemotherapy treated mice. Interestingly, A(3)AR agonists inhibit tumor cell growth both in vitro and in vivo through a cytostatic effect mediated via the de-regulation of the Wnt signaling pathway. The variety of activities elicit by A(3)AR agonists suggest their potential use as therapeutic agents in inflammation, brain/cardiac ischemia and cancer. Antagonists to A(3)AR may be implemented to the therapy of asthma and additional allergic conditions.
引用
收藏
页码:463 / 469
页数:7
相关论文
共 79 条
[1]   Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative disease [J].
Abbracchio, MP ;
Cattabeni, F .
NEUROPROTECTIVE AGENTS: FOURTH INTERNATIONAL CONFERENCE, 1999, 890 :79-92
[2]   The A3 adenosine receptor mediates cell spreading, reorganization of actin cytoskeleton, and distribution of Bcl-xL:: Studies in human astroglioma cells [J].
Abbracchio, MP ;
Rainaldi, G ;
Giammarioli, AM ;
Ceruti, S ;
Brambilla, R ;
Cattabeni, F ;
Barbieri, D ;
Franceschi, C ;
Jacobson, KA ;
Malorni, W .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 241 (02) :297-304
[3]  
Abbracchio MP, 2001, ANN NY ACAD SCI, V939, P63
[4]  
Abbracchio MP, 1998, DRUG DEVELOP RES, V45, P379, DOI 10.1002/(sici)1098-2299(199811/12)45:3/4<379::aid-ddr38>3.0.co
[5]  
2-y
[6]  
Ali H, 1996, J PHARMACOL EXP THER, V276, P837
[7]   ADENOSINE RECEPTOR SPECIFICITY IN PRECONDITIONING OF ISOLATED RABBIT CARDIOMYOCYTES - EVIDENCE OF A(3) RECEPTOR INVOLVEMENT [J].
ARMSTRONG, S ;
GANOTE, CE .
CARDIOVASCULAR RESEARCH, 1994, 28 (07) :1049-1056
[8]   Agonists to the A3 adenosine receptor induce G-CSF production via NF-κB activation:: A new class of myeloprotective agents [J].
Bar-Yehuda, S ;
Madi, L ;
Barak, D ;
Mittelman, M ;
Ardon, E ;
Ochaion, A ;
Cohn, S ;
Fishman, P .
EXPERIMENTAL HEMATOLOGY, 2002, 30 (12) :1390-1398
[9]   Resistance of muscle to tumor metastases: A role for A3 adenosine receptor agonists [J].
Bar-Yehuda, S ;
Barer, F ;
Volfsson, L ;
Fishman, P .
NEOPLASIA, 2001, 3 (02) :125-131
[10]   Apoptosis by 2-chloro-2′-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells [J].
Barbieri, D ;
Abbracchio, MP ;
Salvioli, S ;
Monti, D ;
Cossarizza, A ;
Ceruti, S ;
Brambilla, R ;
Cattabeni, F ;
Jacobson, KA ;
Franceschi, C .
NEUROCHEMISTRY INTERNATIONAL, 1998, 32 (5-6) :493-504